Range of eligible people: CDEC talked over the uncertainty in the quantity of sufferers with reasonably severe to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some people who will be labeled as acquiring delicate or moderate illness might have a severe bleeding phenotype,